SCIENCE-EliteImmune

Identifying elite antibodies created by nature

EliteImmune’s internal programs focus on isolating potent and broad-spectrum therapeutic antibodies from non-progressing, or spontaneously recovered patients, and vaccinated donors. We harness the elite antibodies evolutionarily selected by the human immune system to combat deadly diseases.

At EliteImmune, we combine high-resolution technologies and high-throughput computational approaches into our science-driven rational discovery process, to expedite target validation and monoclonal antibody identification.

Technology

Streamlining therapeutic antibody discovery

EliteImmune has established state-of-the-art technology platforms to accelerate the discovery of potent and broad-spectrum antibody therapeutics.

TECHNOLOGIES WE OFFER

CellsSort is an integrated antigen-specific single B cell manipulation and characterization platform to identify rare antibodies with high therapeutic values from elite donors.

CellSeq is an innovative, user-friendly computational platform that significantly reduces the time and expertise needed to analyze your antibody sequence data from single cells or B cell repertoires

Pipeline

Striving to develop broad and potent targeted therapeutics

At EliteImmune, we combine cutting edge technologies and rigorous scientific research to identify, characterize, and optimize potential immunotherapeutics and vaccines. Our established programs and platforms have resulted in an unparalleled pipeline of broadly neutralizing antibodies (bNAbs) for infectious diseases. We are also poised to expand our R&D spectrum to the oncology and aging field against neoantigens by collaborative and sponsored drug discovery.

Antibody-based subunit vaccines

Our long-term scientific endeavor is to develop prophylactic and therapeutic vaccines instructed by the antibodies we identify and characterize in our early discovery. We apply computational and structural analysis to rationally design subunit vaccines to elicit broadly protective immune responses.

: Lead discovery

: Preclinical

: IND

: PHASE I

: PHASE II

: PHASE III

RSV

Expand

Fully human broadly neutralizing antibody against the respiratory syncytial virus (RSV), an optimized natively paired human monoclonal antibody isolated from an elite donor. The prophylactic candidate displays potent and broad neutralizing activities against diverse RSV clinical isolates. Ongoing next-generation cocktail includes dual therapeutic antibodies targeting distinct epitopes.

Ebola

Expand

First-in-class and best-in-class broadly neutralizing antibody cocktail against the Ebolaviruses. The therapeutic cocktail provides full protection against all pathogenic ebolaviruses in mice, guinea pigs, ferrets, and non-human primates. The research data and detailed descriptions are available on Cell and Nature Communications.

Staph

Expand

Broadly neutralizing antibody cocktail isolated from vaccinated non-human primates and elite donors. Targeted therapeutics against toxins released by Staphylococcal bacteria. Potential passive immunotherapy for the prevention and treatment of Staphylococcal bloodstream infections.

Neoantigen

Expand

Fully human anti-tumor antibody isolated from rare elite controllers. Targeted therapeutic to a specific tumor neoantigen (cancer-specific broadly reactive mAb). Potential passive immunotherapy for the treatment of neoantigen positive patients.

Collaboration

Eliteimmune seeks on-going partnerships and collaborators

EliteImmune is not alone in the journey of combating some of the deadly diseases. We deeply appreciate the partnerships we have built during early discovery, manufacturing, and clinical testing.
We are continuously seeking partnerships and collaborators to expand the spectrum of our best-in-class pipelines for future licensing and development.